Introduction: The increasing resistance of fungal strains to antifungal agents is the main reason of research on the new antifungals. Objectives: The susceptibility analysis of fungal strain isolated from patients hospitalized in Warsaw Medical University Central Clinical Hospital in 2007 to Posaconazole in vitro. Materials and Methods: The clinical material was consisted of: blood samples 33 (43.4%), respiratory tracts specimens (23.7%), wound swabs 16 (21%), urine samples 4 (5.3%) and other 5 (6.6%). Strains were cultured on Sabouraud and CHROMagar media and identify by ID32C tests. The susceptibility analysis to Posaconazole was done according to E-tests. Results: From the total number of 76 positive samples we cultured 87 of fungal strains. The following species were cultured C. galbrata 41 (47%), C. albicans 12 (14%), C. krusi 10 (11.5%), C. parapsilosis 6 (7%), C. inconspicua 4 (4.5%), Saccharomyces cerevisiae 4 (4.5%), other 10 (11.5%). We isolated 83 strains of the yeast like fungi (95% out of all isolates) and two species of molds (5% of all isolates): Aspergillus fumigatus 2 strains and Fusarium incarnatum 2. Our results were analyzed according to ARTEMIS Program. The final Posaconazole concentration was 0,008 to 32ug/ml. In our study the break point was 1 ug/ml and it was established as the agent activity. Posaconazole was active for 83 isolates (95% casus) and it had the break point 1 ug/ml. The all resistant isolates were from the same species of C. glabrata. Posaconazole had not been active for 4 (5%) of isolates. Conclusions: 10% of C. glabrata isolates were Posaconazole resistant. Posaconazole was active for 95% of isolated strains.
Full conference title:
15th International Symposium on Infections in the Immunocompromised Host
- ISIIH 15th